-
公开(公告)号：US20240254251A1
公开(公告)日：2024-08-01
申请号：US18598342
申请日：2024-03-07
申请人： Vor Biopharma Inc.
发明人： Anthony Boitano , Michael Cooke , Charlotte Fenton McDonagh , Rahul Palchaudhuri , Rajiv Panwar , Bradley R. Pearse , Paul Fredrick Widboom , Patricia Ann Cruite
CPC分类号： C07K16/289 , A61K35/28 , A61K47/6803 , A61K47/6849 , A61P35/02 , A61P37/06 , A61K2035/124 , A61K2039/505 , C07K2317/24 , C07K2317/52 , C07K2317/565 , C07K2317/73 , C07K2317/77 , C07K2317/92
摘要： Disclosed are anti-CD45 antibodies, antigen binding fragments thereof, and antibody drug conjugates (ADCs) that specifically bind to human CD45. Such antibodies and ADCs are useful in therapeutic methods, including methods of depleting CD45+ cells from a patient. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD45+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy, and to improve the engraftment of hematopoietic stem cell transplants, by selectively depleting endogenous CD45+ cells prior to the transplant procedure.
-
公开(公告)号：US20240041932A1
公开(公告)日：2024-02-08
申请号：US18026018
申请日：2021-09-14
申请人： VOR BIOPHARMA INC.
发明人： John Lydeard , Tirtha Chakraborty
IPC分类号： A61K35/28 , A61K39/395 , A61K39/00 , C12N15/11 , C12N9/22 , C12N5/0783
CPC分类号： A61K35/28 , A61K39/3955 , A61K39/4611 , A61K39/4631 , C12N15/11 , C12N9/22 , C12N5/0636 , C12N2310/20 , C12N2800/80
摘要： Provided herein are gRNA comprising a targeting domain that targets CD5, which may be used, for example, to make modifications in cells. Also provided herein are methods of genetically engineered cell having a modification (e.g., insertion or deletion) in the CD5 gene and methods involving administering such genetically engineered cells to a subject, such as a subject having a hematopoietic malignancy.
-
公开(公告)号：US20240033290A1
公开(公告)日：2024-02-01
申请号：US18245793
申请日：2021-09-17
申请人： VOR BIOPHARMA INC.
IPC分类号： A61K35/17 , C12N9/22 , C12N5/0783 , A61K45/06 , C12N15/11 , C07K16/28 , A61K39/00 , A61P35/02
CPC分类号： A61K35/17 , C12N9/22 , C12N5/0636 , A61K45/06 , C12N15/11 , C07K16/2803 , A61K39/4611 , A61K39/4631 , A61K39/464411 , A61P35/02 , A61K2239/48
摘要： Provided herein are gRNA comprising a targeting domain that targets CD7, which may be used, for example, to make modifications in cells. Also provided herein are methods of genetically engineered cell having a modification (e.g., insertion or deletion) in the CD7 gene and methods involving administering such genetically engineered cells to a subject, such as a subject having a hematopoietic malignancy.
-
公开(公告)号：US11464807B2
公开(公告)日：2022-10-11
申请号：US17222765
申请日：2021-04-05
申请人： VOR BIOPHARMA INC.
IPC分类号： C12N15/19 , A61K35/28 , A61P35/02 , A61K35/17 , A61K38/17 , A61K39/395 , C12N5/0789 , C12N9/22 , C12N15/11 , C12N15/90 , C07K14/705 , A61P35/00 , A61K35/12 , A61K39/00
摘要： Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
-
公开(公告)号：US10925902B2
公开(公告)日：2021-02-23
申请号：US16701818
申请日：2019-12-03
IPC分类号： A61K35/28 , A61P35/02 , A61K35/17 , A61K39/395 , C12N15/90 , A61K38/17 , C12N5/0789 , C12N9/22 , C12N15/11 , C07K14/705 , A61P35/00 , A61K35/12 , A61K39/00
摘要： Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
-
公开(公告)号：US20200318071A1
公开(公告)日：2020-10-08
申请号：US16813958
申请日：2020-03-10
IPC分类号： C12N5/0789 , C07K14/705 , A61K35/28 , A61K39/395 , A61P35/02
摘要： Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
-
公开(公告)号：US20200138869A1
公开(公告)日：2020-05-07
申请号：US16554520
申请日：2019-08-28
IPC分类号： A61K35/28 , C12N5/0789 , A61P35/00
摘要： Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
-
公开(公告)号：US20240110189A1
公开(公告)日：2024-04-04
申请号：US18023548
申请日：2021-08-27
申请人： VOR BIOPHARMA INC.
发明人： John Lydeard , Chong Luo , Michelle Lin , Jessica Evelyn Lisle
IPC分类号： C12N15/113 , C12N5/0789 , C12N9/22
CPC分类号： C12N15/1138 , C12N5/0647 , C12N9/22 , C12N2310/344 , C12N2510/00
摘要： This disclosure provides, e.g., novel cells having a modification (e.g., insertion or deletion) in the endogenous CLL1 gene. The disclosure also provides compositions, e.g., gRNAs, that can be used to make such a modification.
-
公开(公告)号：US20240000846A1
公开(公告)日：2024-01-04
申请号：US18033461
申请日：2021-10-27
申请人： VOR BIOPHARMA INC.
CPC分类号： A61K35/28 , A61K47/6807 , A61K45/06 , C12N5/0647 , C07K16/2803 , A61P35/02 , A61K9/0019
摘要： Aspects of the disclosure provide methods and compositions for treating a hematopoietic malignancy (e.g., acute myeloid leukemia). In some aspects, the disclosure provides methods of treatment using a population of genetically engineered CD33-deficient hematopoietic cells and a cytotoxic agent comprising an anti-CD33 antigen-binding domain.
-
公开(公告)号：US20230398219A1
公开(公告)日：2023-12-14
申请号：US18026080
申请日：2021-09-14
申请人： VOR BIOPHARMA INC.
CPC分类号： A61K39/464426 , C12N15/11 , C12N9/22 , C12N15/907 , C12N15/111 , A61K39/4611 , A61K39/464411 , A61K39/4622 , A61K39/4631 , C12N2310/20 , C12N2310/321 , C12N2310/315 , A61K2239/17 , A61K2239/21
摘要： Provided herein are gRNA comprising a targeting domain that targets CD38, which may be used, for example, to make modifications in cells. Also provided herein are methods of genetically engineered cell having a modification (e.g., insertion or deletion) in the CD38 gene and methods involving administering such genetically engineered cells to a subject, such as a subject having a hematopoietic malignancy.
-
-
-
-
-
-
-
-
-
搜索结果
38 条记录 (耗时 0.015 秒)
